+44 (0)1526 269069
Established in 2010, we have built a strong presence in the poultry health industry. Since 2011, we have overseen the European market expansion of MS-H, a live Mycoplasma synoviae vaccine which was developed and is manufactured by Bioproperties in Australia. Today, the vast majority of broiler breeders and a significant proportion of commercial layers in the European Union are vaccinated with MS-H Vaccine.
We are proud to have contributed significantly to animal health standards throughout the region because vaccination with MS-H has significantly improved bird health and reduced the amount of antimicrobials used in commercial layers and broiler breeders. Building on this solid foundation, we are pleased to announce that our close working relationship with Bioproperties has been extended with new products and expanded territories. We are excited to broaden our offering in the near future with the introduction of a new live Mycoplasma gallisepticum vaccine based on the MG304 strain.
MG304 is the next generation of live Mycoplasma gallisepticum vaccines. It offers improved biological performance while preserving the trusted safety and efficacy of the TS-11 lineage which it will replace. MG304 is already available in Australia and, subject to regulatory approval, launch in Europe is anticipated in 2027.
Bioproperties have also entrusted us with additional territories and with immediate effect, we will be distributing MSH strain and TS11 strain vaccines throughout the Middle East and in much of North and Sub-Saharan Africa, with the gradual replacement of TS11 by the MG304 strain vaccine.
We are fully committed to long-term partnerships and to delivering high-quality solutions that support sustainable growth in the poultry industry.
Please select both a country and product from the dropdowns.
Please select both a country and product from the dropdowns.
There has been some sort of technical error with the submission. Please try again.
Sorry but there are no matches for that combination.